Phase II/III autism trial shows further benefits
Filed with ASX · · 3 pages · English
Neurotech International Ltd. on 6ix
Story so far
Earlier from Neurotech International
- Significant improvement in Autism patients at 12 weeks
- Phase I/II Autism Patients Meet 2 Years of NTI164 Treatment
- Further clinical benefit at 52 weeks in PANDAS/PANS patients
- Rett Syndrome Phase I/II trial shows significant benefits
- Neurotech Completes $10 Million Capital Raise
Later from Neurotech International
- Further Significant Improvement in Rett Syndrome Patients
- Neurotech Global Partnering and Registration Strategy
- NTI164 Reverses Immune Dysregulation in PANDAS/PANS Children
- US FDA Response to Orphan Drug Request in PANDAS/PANS
- Neurotech Appoints Dr Anthony Filippis as MD/CEO
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International